Goldminz Ari Michael, Gottlieb Alice Bendix
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111, USA.
J Rheumatol Suppl. 2012 Jul;89:86-9. doi: 10.3899/jrheum.120253.
Ustekinumab, which is approved for the treatment of moderate to severe psoriasis, has been shown in phase II clinical trials to be efficacious in controlling the signs and symptoms of psoriatic arthritis. Ustekinumab appears to be well tolerated, but its longterm safety profile is not yet known.
已获批用于治疗中度至重度银屑病的优特克单抗，在II期临床试验中已显示出对控制银屑病关节炎的体征和症状有效。优特克单抗似乎耐受性良好，但其长期安全性尚不清楚。
